Exhibit 10.1


 


SECURITIES PURCHASE AGREEMENT


 


by and between


 


Interleukin Genetics, Inc.


 


and


 


The Purchasers Identified on Schedule
I Hereto


 


December 23, 2014


 




    	 



    	 



    

  


Table
of Contents


 


	 	 	Page
	 	 	 
	1.	PURCHASE AND SALE	1
	 	 	 
	 	(a)	Authorization of Shares	1
	 	 	 	 
	 	(b)	Purchase of Shares and Warrants	1
	 	 	 
	2.	CLOSING	1
	 	 	 
	 	(a)	The Closing	1
	 	 	 	 
	 	(b)	Form of Payment	2
	 	 	 	 
	 	(c)	Conditions to the Purchaser’s Obligation to Purchase on the Closing Date	2
	 	 	 	 
	 	(d)	Conditions to the Company’s Obligation to Issue and Sell on the Closing Date	3
	 	 	 
	3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	4
	 	 	 
	 	(a)	Organization and Qualification	4
	 	 	 	 
	 	(b)	Subsidiaries	4
	 	 	 	 
	 	(c)	Authorization; Enforcement; Validity	4
	 	 	 	 
	 	(d)	Capitalization	5
	 	 	 	 
	 	(e)	Issuance of Shares	6
	 	 	 	 
	 	(f)	No Conflicts	6
	 	 	 	 
	 	(g)	No Violation or Default	6
	 	 	 	 
	 	(h)	SEC Documents	6
	 	 	 	 
	 	(i)	Financial Statements	7
	 	 	 	 
	 	(j)	No Material Adverse Change	7
	 	 	 	 
	 	(k)	Independent Accountants	7
	 	 	 	 
	 	(l)	Title to Intellectual Property	8
	 	 	 	 
	 	(m)	Licenses and Permits; Compliance with Law	8
	 	 	 	 
	 	(n)	Insurance	8
	 	 	 	 
	 	(o)	Related Party Transactions	9
	 	 	 	 
	 	(p)	Environmental Matters	9
	 	 	 	 
	 	(q)	Tax Matters	9


 




    	-i-



    	 



    

  


Table
of Contents


(continued)


 


	 	 	Page
	 	 	 
	 	(r)	Employees	10
	 	 	 	 
	 	(s)	Internal Control over Financial Reporting	10
	 	 	 	 
	 	(t)	Disclosure Controls and Procedures	10
	 	 	 	 
	 	(u)	Sarbanes-Oxley Compliance	10
	 	 	 	 
	 	(v)	Absence of Litigation	10
	 	 	 	 
	 	(w)	Investment Company Act	11
	 	 	 	 
	 	(x)	No Market Manipulation	11
	 	 	 	 
	 	(y)	Foreign Corrupt Practices	11
	 	 	 	 
	 	(z)	Brokers	11
	 	 	 	 
	 	(aa)	Regulation	11
	 	 	 
	4.	PURCHASERS’ REPRESENTATIONS AND WARRANTIES	12
	 	 	 
	 	(a)	Transfer or Resale	12
	 	 	 	 
	 	(b)	Investment Purpose	12
	 	 	 	 
	 	(c)	General Solicitation	12
	 	 	 	 
	 	(d)	Information	12
	 	 	 	 
	 	(e)	Reliance on Exemptions	12
	 	 	 	 
	 	(f)	No Governmental Review	13
	 	 	 	 
	 	(g)	Authorization; Enforcement; Validity	13
	 	 	 	 
	 	(h)	No Conflicts	13
	 	 	 
	5.	RESTRICTIONS ON TRANSFER	13
	 	 	 
	 	(a)	Resales	13
	 	 	 	 
	 	(b)	Rule 144	13
	 	 	 	 
	 	(c)	Legends	14
	 	 	 	 
	 	(d)	Legend Removal	15
	 	 	 	 
	6.	BOARD COMPOSITION	15
	 	 	 	 
	 	(a)	Board Composition; Appointment of Director Designees	15
	 	 	 	 
	 	(b)	Nominations of Director Designees	15
	 	 	 	 
	 	(c)	Successor Director Designees	15


 


 




    	-ii-



    	 



    

  


Table
of Contents


(continued)


 


	 	 	Page
	 	 	 
	 	(d)	Indemnification Agreements	16
	 	 	 	 
	 	(e)	Committees of the Board of Directors	16
	 	 	 	 
	 	(f)	Amendment of this Section 6	16
	 	 	 	 
	 	(g)	Board Observer Rights	16
	 	 	 	 
	7.	OTHER AGREEMENTS AND COVENANTS	17
	 	 	 	 
	 	(a)	National Market Listing	17
	 	 	 	 
	 	(b)	Use of Proceeds	17
	 	 	 	 
	 	(c)	Form D; Blue Sky Filings	17
	 	 	 	 
	 	(d)	Reservation of Shares	17
	 	 	 	 
	 	(e)	Exchange Act Filings	17
	 	 	 	 
	 	(f)	Integration	17
	 	 	 	 
	 	(g)	Expenses	18
	 	 	 	 
	 	(h)	Purchaser/Director Designee Exchange Act Filings	18
	 	 	 
	8.	PUBLIC STATEMENTS	18
	 	 	 
	9.	MISCELLANEOUS	18
	 	 	 
	 	(a)	Governing Law	18
	 	 	 	 
	 	(b)	Entire Agreement	19
	 	 	 	 
	 	(c)	Amendments and Waivers	19
	 	 	 	 
	 	(d)	Notices	19
	 	 	 	 
	 	(e)	No Strict Construction	20
	 	 	 	 
	 	(f)	Further Assurances	20
	 	 	 	 
	 	(g)	Severability	20
	 	 	 	 
	 	(h)	Successors and Assigns	20
	 	 	 	 
	 	(i)	Survival	20
	 	 	 	 
	 	(j)	No Third-Party Beneficiaries	21
	 	 	 	 
	 	(k)	Replacement of Securities	21
	 	 	 	 
	 	(l)	Independent Nature of Purchasers’ Obligations and Rights	21
	 	 	 	 
	 	(m)	Business Day	21


 




    	-iii-



    	 



    

  


Table
of Contents


(continued)


 


	 	 	 	Page
	 	 	 	 
	 	(n)	Headings	21
	 	 	 	 
	 	(o)	Execution	21


 


SCHEDULES


Schedule I – List of Purchasers


 


EXHIBITS


Exhibit A – Form of Warrant


 


Exhibit B – Registration Rights Agreement


 




    	-iv-



    	 



    

  


SECURITIES
PURCHASE AGREEMENT


 


This Securities Purchase Agreement (this
“Agreement”) dated as of December 23, 2014 is made by and between Interleukin Genetics, Inc., a Delaware corporation,
(the “Company”), and each purchaser identified on Schedule I hereto (each a “Purchaser”),
and together, the “Purchasers”). 


 


RECITALS


 


In accordance with the terms and conditions
of this Agreement and pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities
Act”), the Company has agreed to issue and sell, and each Purchaser has agreed, severally and not jointly, to purchase
a number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and
a warrant to purchase a number of shares of Common Stock (the “Warrant”, and together with all such warrants
being issued to Purchasers under this Agreement, the “Warrants”), each as set forth opposite such Purchaser’s
name on Schedule I to this Agreement.


 


NOW THEREFORE, in consideration of the promises
and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and each Purchaser hereby agree as follows:


 


1.          PURCHASE
AND SALE


 


(a)     Authorization
of Shares. The Company has authorized (i) the sale and issuance to the Purchasers of the shares of Common Stock, (ii)
the sale and issuance to the Purchasers of the Warrants, and (iii) the issuance of shares of Common Stock to be issued upon
exercise of the Warrants (the “Warrant Shares”).


 


(b)      Purchase
of Shares and Warrants. At the Closing (as defined below), the Company shall issue and sell to each Purchaser, and each Purchaser
shall, severally and not jointly, purchase from the Company, upon the terms and subject to the conditions set forth in this Agreement,
(i) the number of shares of Common Stock set forth opposite such Purchaser’s name on Schedule I to this Agreement
(the “Shares”) and (ii) a Warrant to purchase the number of shares of Common Stock set forth opposite such
Purchaser’s name on Schedule I to this Agreement, for an aggregate purchase price as set forth opposite such Purchaser’s
name on Schedule I to this Agreement (the “Purchase Price”), based on a purchase price per Share of
$0.1003 (the “Per Share Purchase Price”).


 


2.          CLOSING


 


(a)      The
Closing. The date and time of the Closing of the purchase and sale of the Shares and the Warrants (the “Closing”)
shall occur on December 23, 2014 at 12:00 p.m. Boston time, at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
One Financial Center, Boston, Massachusetts, 02111 (subject to the satisfaction or waiver of the conditions set forth in Subsections
(c) and (d) of this Section 2), or at such other location, date and time as may be agreed upon between the Company and the Purchasers
(the “Closing Date”).


 




    	 



    	 



    

  


(b)      Form
of Payment. On the Closing Date, each Purchaser shall pay the Company the Purchase Price for the Shares and the Warrant to
be issued and sold to such Purchaser on such Closing Date, by wire transfer of immediately available funds in accordance with the
Company’s written wire instructions previously provided to the Purchasers, and the Company shall deliver to each Purchaser
the original certificate or certificates representing the Shares and the original Warrant, duly executed on behalf of the Company
and registered in the name of such Purchaser.


 


(c)      Conditions
to the Purchaser’s Obligation to Purchase on the Closing Date. Each Purchaser’s obligation to purchase the Shares
and the Warrant at the Closing shall be subject to the satisfaction, on or before the Closing Date, of each of the following conditions,
provided that these conditions are for the Purchaser’s sole benefit and may be waived by such Purchaser at any time in its
sole discretion:


 


		(i)	receipt of a copy of this Agreement executed by the Company;



 


		(ii)	the Company shall have entered into an agreement with Horizon
Technology Finance Management LLC and/or its assignees and/or other lenders with respect to a $5,000,000 venture loan (the “Venture
Loan Agreement”);



 


		(iii)	evidence of irrevocable instructions from the Company to
the transfer agent for the Common Stock with respect to the issuance and delivery of one or more certificates representing the
Shares;



 


		(iv)	receipt of the Warrant in the form attached as Exhibit
A;



 


		(v)	all actions required by the Board of Directors of the Company
(the “Board”) to effect the provisions of Section 6 of this Agreement with respect to the composition of the
Board following the Closing shall have been taken;



 


		(vi)	all consents, approvals and waivers required for the consummation
of the transactions contemplated hereby shall have been obtained;



 


		(vii)	the Company shall have delivered to the Purchasers a Compliance
Certificate, executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the effect that the conditions
specified in subsections (vi), (ix), and (x) of this Section 2(c) have been satisfied;



 


		(viii)	the Company shall have delivered to the Purchasers a certificate
of its Secretary certifying as to (A) the resolutions of the Board approving this Agreement and the transactions contemplated
hereby, including the actions required by the Company pursuant to this Section 2(c); and (B) good standing certificates
(including tax good standing) with respect to the Company from the applicable authority(ies) in Delaware and any other jurisdiction
in which the Company is qualified to do business dated a recent date before the Closing;



 




    	-2-



    	 



    

  


		(ix)	the representations and warranties of the Company in this
Agreement shall be true, correct and complete as of the Closing Date (except for representations and warranties that speak as
of a specific date, which shall be true, correct and complete as of such date) and the Company shall have performed, satisfied
and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed,
satisfied or complied with by the Company at or prior to the Closing;



 


		(x)	no temporary restraining order, preliminary or permanent
injunction or other order or decree, and no other legal restraint or prohibition, shall exist which questions the validity of
this Agreement or the right of the Company or any Purchaser, as the case may be, to enter into this Agreement or prevents or could
reasonably be expected to prevent the consummation of the transactions contemplated by this Agreement, nor shall any litigation
or court or administrative proceeding have been commenced or threatened with respect to the foregoing;



 


		(xi)	the Company shall have executed and delivered the Registration
Rights Agreement in substantially the form attached as Exhibit B (the “Registration Rights Agreement”);



 


		(xii)	delivery of a legal opinion of Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, Company counsel, in form and substance reasonably satisfactory to the Purchasers; and



 


		(xiii)	receipt of such other information, certificates and documents
as the Purchasers may reasonably request.



 


(d)      Conditions
to the Company’s Obligation to Issue and Sell on the Closing Date. The Company’s obligation to issue and sell the
Shares and the Warrant at the Closing shall be subject to the satisfaction, on or before the Closing Date, of each of the following
conditions, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time
in its sole discretion:


 


		(i)	receipt of a copy of this Agreement executed by each Purchaser;



 


		(ii)	receipt of the Purchase Price from each Purchaser;



 


		(iii)	the representations and warranties of each Purchaser in
this Agreement shall be true, correct and complete as of the date of this Agreement and as of the Closing Date (except for representations
and warranties that speak as of a specific date, which shall be true, correct and complete as of such date) and each Purchaser
shall have performed, satisfied and complied with in all material respects the covenants, agreements and conditions of such Purchaser
to be performed, satisfied or complied with by it under this Agreement at or prior to the Closing Date; and



 




    	-3-



    	 



    

  


		(iv)	no temporary restraining order, preliminary or permanent
injunction or other order or decree, and no other legal restraint or prohibition shall exist which questions the validity of this
Agreement or the right of the Company or any Purchaser, as the case may be, to enter into this Agreement or prevents or could
reasonably be expected to prevent the consummation of the transactions contemplated by this Agreement, nor shall any litigation
or court or administrative proceeding have been commenced or threatened with respect to the foregoing.



 


3.          REPRESENTATIONS
AND WARRANTIES OF THE COMPANY


 


The Company represents and warrants to each
Purchaser, subject to such exceptions as are set forth in the SEC Documents (as defined below) (other than (x) those sections of
the SEC Documents entitled or captioned “Risk Factors,” (y) any disclosure of risks included in any forward-looking
statements disclaimer or other statements that are similarly non-specific and are predictive or forward looking in nature and (z)
specific disclosures contained in those documents which are filed as exhibits to the SEC Documents), provided that the relevance
of such exceptions to the representations and warranties is reasonably apparent, as follows:


 


(a)      Organization
and Qualification. The Company is a corporation, duly organized, validly existing and in good standing under the laws of the
State of Delaware, and has the requisite corporate power and authority to own its properties and to carry on its business as now
being conducted and as described in the SEC Documents. Copies of the Company’s Restated Certificate of Incorporation (the
“Charter”) and Amended and Restated Bylaws of the Company, as amended (the “Bylaws”), and
in each case, all amendments thereto, have been filed as exhibits to the Company’s SEC Documents and have not been further
modified, and except as otherwise may be required by the transactions contemplated hereby, the Company has no present intention
to modify the Charter and Bylaws. The Company is duly qualified as a foreign corporation to do business, and is in good standing,
in every jurisdiction in which its ownership of property or the nature of the business conducted and proposed to be conducted by
it makes such qualification necessary, except where the failure to be so qualified or in good standing would not, individually
or in the aggregate, have or reasonably be expected to result in a material adverse effect on (i) the condition (financial or otherwise),
prospects, earnings, assets, results of operations, business or properties of the Company, whether or not arising from transactions
in the ordinary course of business or (ii) the ability of the Company to consummate the transactions contemplated by this Agreement
(“Material Adverse Effect”).


 


(b)      Subsidiaries.
The Company has no subsidiaries.


 


(c)      Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement, the Registration Rights Agreement, the Venture Loan Agreement and each of the other agreements entered into
by the parties hereto in connection with transactions contemplated by this Agreement (collectively, the “Transaction Documents”)
and to issue the Shares and the Warrants in accordance with the terms hereof and thereof. The execution and delivery of the Transaction
Documents by the Company and the consummation and performance by the Company of the transactions contemplated hereby and thereby,
including, without limitation, the issuance of the Shares, Warrants and the Warrant Shares (collectively, the “Securities”),
have been duly authorized by all requisite corporate action. The Transaction Documents have been duly executed and delivered by
the Company. The Transaction Documents constitute the valid and binding obligations of the Company enforceable against the Company
in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’
rights and remedies.


 




    	-4-



    	 



    

  


(d)      Capitalization.
As of the date of this Agreement, the authorized capital stock of the Company consists of (i) 300,000,000 shares of Common Stock
and (ii) 6,000,000 shares of undesignated preferred stock, $0.001 par value per share. As of the date of this Agreement and prior
to the issuance of the Shares and Warrants under this Agreement, (i) 122,583,642 shares of Common Stock are issued and outstanding;
(ii) 4,523,900 shares of Common Stock are duly reserved for future issuance pursuant to outstanding stock options; (iii) 37,269,126
shares of Common Stock are duly reserved for future issuance pursuant to outstanding warrants; (iv) 5,954,825 shares of Common
Stock are duly reserved for future issuance pursuant to the Company’s stock plans; and (v)  503,952 shares of Common
Stock are duly reserved for future issuance pursuant to the Company’s employee stock purchase plan. All of the issued shares
of capital stock of the Company have been duly and validly authorized and issued, are fully paid and non-assessable, and have been
issued in compliance with federal and state securities laws. Except as set forth above, (i) no shares of the Company’s capital
stock are subject to preemptive rights or any other similar rights or any liens or encumbrances; (ii) there are no outstanding
options, warrants, rights to subscribe to, calls or commitments relating to, or securities or rights convertible into, any shares
of capital stock of the Company, or contracts, commitments, understandings or arrangements by which the Company is or may become
bound to issue additional shares of capital stock of the Company or options, warrants, rights to subscribe to, calls or commitments
relating to, or securities or rights convertible into, any shares of capital stock of the Company. The Company has no knowledge
of any voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among
any of the security holders of the Company relating to the securities of the Company held by them. Other than (i) pursuant to the
Registration Rights Agreement, (ii) with respect to the shares of Common Stock issuable upon exercise of the warrant to be issued
pursuant to the Venture Loan Agreement, and (iii) except as set forth in that certain Registration Rights Agreement, dated May
17, 2013, between the Company and the purchasers signatory thereto, the Company has not granted any person the right to require
the Company to register any securities of the Company under the Securities Act, whether on a demand basis or in connection with
the registration of securities of the Company for its own account or for the account of any other person.


 




    	-5-



    	 



    

  


(e)      Issuance
of Shares. The Shares and the Warrant Shares have been duly and validly reserved for issuance. The Shares and the Warrant Shares
are duly authorized and, upon issuance in accordance with the terms hereof and the Warrants, will be (A) validly issued, fully
paid and non-assessable and (B) free from all taxes, liens and charges in the United States of America with respect to the issuance
thereof, other than any liens or encumbrances created by or imposed by the Purchaser, and not subject to preemptive, registration,
right of first refusal or other similar rights of stockholders of the Company. Except for the filing of any notice prior or subsequent
to the Closing that may be required under applicable state and/or federal securities laws (or comparable laws of any other jurisdiction),
no authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department,
commission, board, bureau, agency, instrumentality or other third party, is or will be necessary for, or in connection with, the
execution and delivery by the Company of this Agreement, for the offer, issue, sale, execution or delivery of the Shares and Warrants,
or for the performance by the Company of its obligations under this Agreement. The Company has reserved from its duly authorized
capital stock the Shares and the Warrant Shares.


 


(f)      No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby do not and will not (i) result in a breach or violation of the Company’s
Charter or Bylaws; (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or incremental, additional
or varied rights under, any agreement, indenture, or other instrument, obligation or understanding to which the Company is a party;
(iii) result in a violation of any statute, law, rule, regulation, order, judgment or decree (including federal and state securities
laws) applicable to the Company; or (iv) result in the imposition of a mortgage, pledge, security interest, encumbrance, charge
or other lien on any asset of the Company.


 


(g)      No
Violation or Default. The Company is not (i) in violation of its Charter or Bylaws; (ii) in default (or subject to an event
which with notice or lapse of time or both would become a default) under any agreement, indenture or instrument to which the Company
is a party; or (iii) in violation of any law, rule, regulation, order, judgment or decree applicable to the Company; except for
such violations or defaults, as described in clauses (ii) or (iii) of this sentence as would not, individually or in the aggregate,
have or result in a Material Adverse Effect.


 


(h)      SEC
Documents. The Company has filed all reports, schedules, forms, statements, exhibits (including certifications of the Company’s
principal executive and financial officers pursuant to Section 302 and 906 of Sarbanes-Oxley (as defined below)) and other documents
required to be filed by it with the U.S. Securities and Exchange Commission (“SEC”) pursuant to the reporting
requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since January 1, 2013
(all of the foregoing filed prior to or on the date hereof, or prior to the Closing Date, and all exhibits included therein and
financial statements and schedules thereto and documents incorporated by reference therein being referred to in this Agreement
as the “SEC Documents”). As of the date of filing of each such SEC Document, such SEC Document, as it may have
been subsequently amended by filings made by the Company with the SEC prior to the date hereof, complied in all material respects
with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to such SEC
Document. None of the SEC Documents, as of the date filed and as they may have been subsequently amended by filings made by the
Company with the SEC prior to the date hereof, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading.


 




    	-6-



    	 



    

  


(i)      Financial
Statements. The financial statements and the related notes thereto of the Company included or incorporated by reference in
the SEC Documents comply in all material respects with the applicable requirements of the Exchange Act and present fairly and accurately
in all material respects the financial position of the Company as of the dates indicated and the results of operations and the
changes in cash flows for the periods specified. Such financial statements have been prepared in conformity with United States
generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods covered
thereby, except as specifically stated therein, and the supporting schedules included or incorporated by reference in the SEC Documents
present fairly the information required to be stated therein. The Company does not have any material liability or obligation of
any nature, whether or not accrued, contingent or otherwise that would be required by GAAP to be disclosed on a balance sheet of
the Company or in the notes thereto. The Company has not created any entities or entered into any transactions or created any liabilities
or obligations of any nature, whether or not accrued, contingent or otherwise, for the purpose of avoiding disclosure required
by GAAP.


 


(j)      No
Material Adverse Change. Since the date of the most recent financial statements of the Company included or incorporated by
reference in the SEC Documents, except as disclosed in the SEC Documents and as contemplated by this Agreement and the Venture
Loan Agreement, (i) there has not been any change in the capital stock (other than pursuant to the Company's stock plans pursuant
to the Company's existing employee stock purchase plan (any such issuances, whenever issued or granted, being collectively “Employee
Equity Transactions”), pursuant to the conversion or exercise of outstanding securities that are convertible into or
exercisable for Common Stock, or pursuant to publicly disclosed equity or debt financings) or long-term debt of the Company, or
any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock;
(ii) the Company has not entered into any transaction or agreement that is material to the Company taken as a whole or incurred
any liability or obligation, direct or contingent, that is material to the Company and, except as contemplated by this agreement,
has not made any material change or amendment to a material contract or arrangement by which the Company or any of its assets or
properties is bound or subject; (iii) the Company has not sustained any material loss or interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action,
order or decree of any court or arbitrator or governmental or regulatory authority; and (iv) there has not been the occurrence
of any Material Adverse Effect.


 


(k)      Independent
Accountants. Grant Thornton LLP, who have certified certain financial statements of the Company, have advised the Company that
they are, and to the Company’s knowledge they are, independent registered public accountants with respect to the Company
as required by the Securities Act. Except as pre-approved in accordance with the requirements set forth in Section 10A of the Exchange
Act, to the Company’s knowledge, Grant Thornton LLP has not engaged in any “prohibited activities” (as defined
in Section 10A of the Exchange Act) on behalf of the Company.


 




    	-7-



    	 



    

  


(l)      Title
to Intellectual Property. The Company owns or possesses adequate rights to use all patents, patent applications, trademarks,
service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, know-how and
all other intellectual property rights (including trade secrets and other unpatented or unpatentable proprietary or confidential
compounds, genes, information, systems or procedures) (collectively, the “Intellectual Property”), used in or
necessary for the conduct of the Company’s business as now, or as contemplated to be, conducted. Except as set forth in the
SEC Documents, (i) there are no rights of third parties to any such Intellectual Property except through licensing or cross-licensing
agreements; (ii) to the Company’s knowledge, there is no infringement by third parties of any Intellectual Property
to which the Company can assert a claim of infringement; (iii) there is no pending or, to the Company’s knowledge, threatened
action, suit, proceeding or claim by others challenging the Company’s ownership of or licensing rights in or to any such
Intellectual Property; (iv) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding
or claim by others challenging the validity or scope of any such Intellectual Property, other than ordinary patent, trademark,
service mark and copyright prosecution disclosed in the SEC Documents; (v) there is no pending or, to the Company’s
knowledge, threatened action, suit, proceeding or claim by others that the Company infringes or otherwise violates any Intellectual
Property of others, and the Company is unaware of any reasonable basis for any such claim; (vi) the Company has not been and
will not be required to utilize any inventions, trade secrets or proprietary information of any of its employees made prior to
their employment by the Company; (vii) the Company has taken all steps required to perfect its ownership of and interest in
its Intellectual Property; and (viii) the Company has taken reasonable security measures to protect the secrecy, confidentiality
and value of all of its Intellectual Property.


 


(m)      Licenses
and Permits; Compliance with Law. The Company possesses all licenses, certificates, permits and other authorizations issued
by, and has made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities, that are necessary for the ownership or lease of its properties and assets or the conduct of its business as conducted
or as contemplated to be conducted. The Company has not received notice of any revocation or modification of any such license,
certificate, permit or authorization, or of any proceeding relating to any such revocation or modification, or has any reason to
believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course. The Company has
complied in all material respects with and is not in default or violation in any material respect of, and is not, to the Company’s
knowledge, under investigation with respect to or has not been, to the knowledge of the Company, threatened to be charged with
or given notice of any violation of, any applicable federal, state, local or foreign law, statute, ordinance, license, rule, regulation,
policy or guideline, order, demand, writ, injunction, decree or judgment of any federal, state, local or foreign governmental or
regulatory authority. Except for statutory or regulatory restrictions of general application, no federal, state, local or foreign
governmental or regulatory authority has placed any material restriction on the business or properties of the Company.


 


(n)      Insurance.
The Company maintains insurance of the types and in the amounts that the Company reasonably believes are adequate for its businesses
and consistent with insurance coverage maintained by similar companies in similar businesses, including, but not limited to, insurance
covering real and personal property owned or leased by the Company against theft, damage, destruction, acts of vandalism, insurance
covering the acts and omissions of directors and officers, and insurance covering all other risks customarily insured against by
similarly situated companies, all of which insurance is in full force and effect. The Company has not received any written notice
that the Company will not be able to renew its existing insurance coverage as and when such coverage expires.


 




    	-8-



    	 



    

  


(o)      Related
Party Transactions. Except as contemplated by this Agreement, none of the officers or directors of the Company and, to the
knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the
furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000
other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) for other employee benefits, including stock option agreements under any stock option plan of the
Company.


 


(p)      Environmental
Matters. The Company is in compliance with all foreign, federal, state and local rules, laws and regulations relating to the
use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment
which are applicable to their businesses. To the Company’s knowledge, there has been no storage, generation, transportation,
handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous substances
by, due to, or caused by the Company (or, to the Company’s knowledge, any other entity for whose acts or omissions the Company
is or may be liable) upon any of the property now or previously owned or leased by the Company, or upon any other property, in
violation of any statute or any ordinance, rule, regulation, order, judgment, decree or permit or which would, under any statute
or any ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability.
There has been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding
such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge.


 


(q)      Tax
Matters. The Company (i) has timely filed all necessary federal, state, local and foreign income and franchise tax returns
or has requested extensions thereof, (ii) has paid all federal state, local and foreign taxes due and payable for which it is liable,
except for any such taxes currently being contested in good faith, and (iii) does not have any tax deficiency or claims outstanding
or assessed or, to the best of the Company’s knowledge, proposed against it. All material taxes and other assessments and
levies that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the
proper government entity or third party when due. There are no tax liens or claims pending or, to the Company’s knowledge,
threatened against the Company or any of its respective assets or property. Except as set forth in the SEC Documents, there are
no outstanding tax sharing agreements or other such arrangements between the Company and any other Person.


 




    	-9-



    	 



    

  


(r)      Employees.
All current and former employees of the Company have executed and delivered a confidential information and inventions assignment
agreement (a “CIIA”) to the Company. All current and former consultants of the Company that had access to confidential
or proprietary information of the Company have executed and delivered a CIIA to the Company or other form of written contract or
agreement with the Company that requires such consultants to maintain the confidentiality of such information and assigns to the
Company all rights to any inventions, improvements, discoveries or information relating to the business of the Company. The Company
is not aware that any executive officer of the Company has plans to terminate his or her employment relationship with the Company.
The Company has complied in all material respects with all applicable laws relating to wages, hours, equal opportunity, collective
bargaining, workers’ compensation insurance and the payment of social security and other taxes. None of the employees of
the Company is represented by any labor union, and there is no labor strike or other labor trouble pending or, to the Company’s
knowledge, threatened with respect to the Company. To the Company’s knowledge, no employee of the Company is obligated under
any contract or subject to any judgment, decree or administrative order that would conflict or interfere with (i) the performance
of the employee’s duties as an employee, director or officer of the Company, or (ii) the Company’s business as conducted
or proposed to be conducted.


 


(s)      Internal
Control over Financial Reporting. The Company maintains a system of internal control over financial reporting (as such is defined
in Rule 13a-15(f) of the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by the Company’s
principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.
The Company does not have any material weaknesses in its internal control over financial reporting. Since the date of the latest
audited financial statements included in the SEC Documents, there has been no change in the Company’s internal control over
financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control
over financial reporting.


 


(t)      Disclosure
Controls and Procedures. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e)
of the Exchange Act) that comply with the requirements of the Exchange Act. Such disclosure controls and procedures have been designed
to ensure that material information relating to the Company is accumulated and communicated to the Company’s management,
including the Company’s principal executive officer and principal financial officer, by others within those entities.


 


(u)      Sarbanes-Oxley
Compliance. The Company and the Company’s directors and officers, in their capacities as such, are in compliance with
any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (“Sarbanes-Oxley”),
including Section 402 related to loans and Sections 302 and 906 related to certifications, and neither the Company nor any of its
officers has received notice from any governmental entity questioning or challenging the accuracy, completeness, content, form
or manner of filing or submission of such certifications. The Company has no reasonable basis to believe that it will not continue
to be in compliance with Sarbanes-Oxley as in effect on the Closing Date (including, without limitation, the requirements of Section
404 thereof).


 


(v)         Absence
of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened in writing against the Company
which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or the Securities or
(ii) would reasonably be expected to result in a Material Adverse Effect.


 




    	-10-



    	 



    

  


(w)      Investment
Company Act. The Company is not, nor, after giving effect to the sale of the Shares and the Warrants and the application of
the proceeds therefrom, will it become, an “investment company” within the meaning of the Investment Company Act of
1940, as amended, and the rules and regulations of the SEC thereunder.


 


(x)      No
Market Manipulation. Neither the Company nor, to the knowledge of the Company, any of the Company’s directors, officers,
employees, agents or controlling persons have taken, directly or indirectly, any action designed, or that might reasonably be expected,
to cause or result in, under the Securities Act or otherwise, or that has constituted, stabilization or manipulation of the price
of the Common Stock.


 


(y)      Foreign
Corrupt Practices. Neither the Company nor, to the Company’s knowledge, any director, officer, agent, employee or other
person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company, (i) directly or indirectly,
used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity;
(ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds;
(iii) violated or is in violation of in any material respect any provision of the U.S. Foreign Corrupt Practices Act of 1977, as
amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign
or domestic government official or employee.


 


(z)      Brokers.
Except pursuant to the agreement with BTIG, LLC (the “Placement Agent”), neither the Company nor any of the
Company's officers, directors, employees or stockholders has employed or engaged any broker or finder in connection with the transactions
contemplated by this Agreement and no other fee or other compensation is or will be due and owing to any broker, finder, underwriter,
placement agent or similar person in connection with the transactions contemplated by this Agreement.


 


(aa)         Regulation.
Assuming the accuracy of the representations and warranties made by the Purchasers in Section 4 of this Agreement, the offer, issuance,
sale and delivery of the Securities are or will be exempt from the registration requirements of the Securities Act and the qualification
or registration provisions of applicable state securities laws. Neither the Company nor its authorized agents have taken or will
take any action that would cause the loss of such exemption. Neither the Company nor any person acting on its behalf has conducted
any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or
sale of any of the Securities. Neither the Company nor any of its affiliates, nor any person acting on its or their behalf has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would adversely affect reliance by the Company on Section 4(2) of the Securities Act for the exemption from registration
for the contemplated transactions under this Agreement or would require registration of the Shares or the Common Shares under the
Securities Act.


 




    	-11-



    	 



    

  


4.          PURCHASERS’
REPRESENTATIONS AND WARRANTIES


 


Each Purchaser, for itself and for no other
Purchaser, hereby represents and warrants to the Company as follows:


 


(a)      Transfer
or Resale. The Purchaser understands that the Securities have not been registered under the Securities Act or any state securities
laws, and may not be offered for sale, sold, assigned or transferred without registration under the Securities Act or an exemption
therefrom and that, in the absence of an effective registration statement under the Securities Act, such Securities may only be
sold under certain circumstances as set forth in the Securities Act.


 


(b)      Investment
Purpose. The Purchaser is acquiring the Securities for its own account for investment only and not with a view towards, or
for resale in connection with, the public sale or distribution thereof. The Purchaser does not have any agreement or understanding,
directly or indirectly, with any person to distribute any of the Securities.


 


(c)      General
Solicitation. The Purchaser was contacted regarding the sale of the Securities by an authorized representative of the Company
or the Placement Agent with whom the Purchaser has a prior substantial pre-existing relationship and the Purchaser is not purchasing
the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any
newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation
or general advertisement.


 


(d)      Information.
The Purchaser (directly or through its advisors, if any) (i) has been furnished with or has had full access to all of the publicly
available information that it considers necessary or appropriate for deciding whether to purchase the Securities, (ii) has had
an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the
Securities, (iii) can bear the economic risk of a total loss of its investment in the Securities and (iv) has such knowledge and
experience in business and financial matters so as to enable it to understand the risks of and form an investment decision with
respect to its investment in the Securities. The Purchaser has received no representation or warranties from the Company, its employees,
agents (including the Placement Agent), or attorneys in making this investment decision other than as set forth in the Transaction
Documents.


 


(e)      Reliance
on Exemptions. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Warrants, it will be either: (i) an “accredited investor” as defined in Rule 501(a)
under the Securities Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities
Act. The Purchaser understands that the Securities are being offered and sold to it in reliance on specific exemptions from the
registration requirements of the Securities Act and that the Company is relying upon the truth and accuracy of, and the Purchaser’s
compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Purchaser set forth in
this Agreement in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire the Securities.


 




    	-12-



    	 



    

  


(f)      No
Governmental Review. The Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.


 


(g)      Authorization;
Enforcement; Validity. The Purchaser is an entity duly organized and validly existing under the laws of the jurisdiction of
its organization with full right, corporate or limited partnership power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution, delivery and performance by
the Purchaser of the transactions contemplated by this Agreement has been duly authorized by all necessary corporate or limited
partnership action on the part of the Purchaser and any other governmental action with respect to the Purchaser.  This Agreement
has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with terms hereof, will constitute the
valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms, except as such enforceability
may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.


 


(h)      No
Conflicts. The execution, delivery and performance of this Agreement by the Purchaser and the consummation by the Purchaser
of the transactions contemplated hereby do not and will not (i) result in a violation of the Purchaser’s charter, bylaws,
or other similar organizational documents; (ii) conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) under any agreement, indenture or other instrument, obligation or understanding to which
the Purchaser is a party; or (iii) result in a violation of any law, rule, regulation, order, judgment or decree applicable to
the Purchaser, except for such conflicts, defaults and violations as described in clauses (ii) or (iii) of this sentence as would
not, individually or in the aggregate, have or result in a material adverse effect on the Purchaser.


 


5.           RESTRICTIONS
ON TRANSFER


 


(a)      Resales.
Each Purchaser agrees that the Securities may only be sold or transferred (i) pursuant to an effective registration statement under
the Securities Act (including the Registration Statement (as defined in the Registration Rights Agreement)), or (ii) pursuant to
an exemption from registration under the Securities Act.


 


(b)      Rule
144. Each Purchaser is aware of Rule 144 promulgated by the SEC pursuant to the Securities Act (as such rule may be amended
or interpreted from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same
purpose and effect as such rule, “Rule 144”) and the restrictions imposed thereby and further understands and
agrees that so long as such Purchaser beneficially owns 10% or more of the Company’s then outstanding securities or has a
designee selected by the Purchaser serving on the Board, the Company will deem the Purchaser to be an “affiliate” as
defined in Rule 144(a)(1) and any transfers of the Securities by the Purchaser shall be subject to the limitations applicable to
affiliates set forth in the Securities Act and the rules promulgated thereunder, including without limitation Rule 144.


 




    	-13-



    	 



    

  


(c)      Legends.
Each Purchaser agrees to the imprinting, so long as is required by this Section 5, of a legend on any of the Securities in substantially
the following form:


 


“THIS SECURITY HAS NOT
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE
OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL
BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED
BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a)
UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.”


 


The Company acknowledges and agrees that a Purchaser may from
time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some
or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under
the Securities Act and who agrees to be bound by the provisions of this Agreement and the Registration Rights Agreement and, if
required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured
parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the
pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge.
At the appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or
secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the
Securities are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required
prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately
amend the list of Selling Stockholders (as defined in the Registration Rights Agreement) thereunder.


 




    	-14-



    	 



    

  


(d)      Legend
Removal. The Company shall cause its counsel to promptly issue a legal opinion to the transfer agent for the Common Stock with
respect to removal of the legend set forth in Section 5(c) above, (i) following any sale of such Shares or Warrant Shares pursuant
to an effective registration statement, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144, or (iii)
when such Shares or Warrant Shares may be sold under Rule 144, without the requirement for the Company to be in compliance with
the current public information required under Rule 144 as to such Shares and Warrant Shares and without volume or manner-of-sale
restrictions.


 


6.          BOARD
COMPOSITION


 


(a)      Board
Composition; Appointment of Director Designees. The Board shall take all actions necessary such that the Board shall consist
of seven (7) members and shall be composed as follows:


 


(i)          the
Class I directors with a term ending at the 2016 annual meeting of stockholders shall consist of one independent director (currently
William C. Mills III) and one director designated by Pyxis Innovations Inc. (currently Joseph M. Landstra) (a “Pyxis Designee”);


 


(ii)         the
Class II directors with a term ending at the 2017 annual meeting of stockholders shall consist of the Company’s Chief Executive
Officer and one director designated by Bay City Capital Fund V, L.P. (currently Dayton Misfeldt) (a “BCC Designee”);
and


 


(iii)        the
Class III directors with a term ending at the 2015 annual meeting of stockholders shall consist of one director designated by Pyxis
Innovations Inc. (currently Roger C. Colman) (a “Pyxis Designee”), one independent director (currently James
Weaver), and one director designated by Bay City Capital Fund V, L.P. (currently Lionel Carnot) (a “BCC Designee”).


 


The Pyxis Designees and the BCC Designees, shall be collectively
referred to herein as the “Director Designees.” Each of the shareholders entitled to designate a director hereunder
is referred to herein as a “Designor.” The rights provided under this Section 6 are the exclusive rights of
each such Designor and are not transferable.


 


(b)      Nominations
of Director Designees. For so long as a Designor’s ownership of the outstanding Common Stock of the Company is at least
five percent (5%), any Director Designee (including any successor pursuant to Subsection 6(c) below) designated by such Designor
shall be nominated by the Board of Directors (or a committee thereof) for election at the annual meeting of stockholders at which
such Director Designee’s term will expire. At least ninety (90) days prior to any such annual meeting at or by which directors
are to be elected, such Designor shall notify the Company in writing of the Director Designee to be nominated for election as a
director. The Company shall disclose in its proxy the nominated Director Designee(s). In the absence of any such notification,
it shall be presumed that the Designor’s then incumbent Director Designee(s) has been designated.


 


(c)      Successor
Director Designees. If a Director Designee shall cease to serve as a director for any reason, the Designor of such Director
Designee shall notify the Company in writing of the individual to replace such Director Designee, and the Company’s Board
of Directors shall appoint and elect such replacement director to serve out the remaining term of the existing director.


 




    	-15-



    	 



    

  


(d)      Indemnification
Agreements. The Company shall enter into an Indemnification Agreement with each successor Director Designee prior to the commencement
of his or her service on the Board.


 


(e)      Committees
of the Board of Directors. For so long as the Designor of the BCC Designees has the right to designate Director Designees and
provided that such individuals meet the requirements imposed by the SEC or any exchange upon which the Common Stock may be traded
for membership on such committees, the Board shall appoint a BCC Designee to the Audit Committee, the Compensation Committee and
the Nominating and Governance Committee. For so long as the Designor of the Pyxis Designees has the right to designate Director
Designees and provided that such individual meets the requirements imposed by the SEC or any exchange upon which the Common Stock
may be traded for membership on such committee, the Board shall appoint a Pyxis Designee to the Audit Committee.


 


(f)      Amendment
of this Section 6. For so long as Pyxis Innovations Inc. has the right to designate a Pyxis Designee, no provision of this
Section 6 may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment,
by the Company, the Purchasers holding at least a majority in interest of the Shares then outstanding (which amendment shall be
binding on all Purchasers) and Pyxis Innovations Inc. or, in the case of a waiver, by the party against whom enforcement of any
such waived provision is sought. For so long as Bay City Capital Fund V, L.P. has the right to designate a BCC Designee, no provision
of this Section 6 may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment,
by the Company, the Purchasers holding at least a majority in interest of the Shares then outstanding (which amendment shall be
binding on all Purchasers) and Bay City Capital Fund V, L.P. or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought.


 


(g)      Board
Observer Rights. For so long as a Growth Equity Opportunities Fund III, LLC’s (“GEOF”) ownership of
the outstanding Common Stock of the Company is at least five percent (5%), GEOF shall have the right to have a representative (the
“Observer”) attend each meeting of the Board. The Company shall deliver to the Observer notice of such meetings
in accordance with the Company’s Bylaws. Copies of any materials distributed to members of the Board shall likewise be provided
to the Observer in a timely fashion. The Company shall not be required to deliver to the Observer specific information, and may
preclude the Observer from specific discussions of the Board of Directors concerning specific information, that (i) is determined
by the Board of Directors of the Company to be competitively sensitive, (ii) the Board of Directors of the Company determines is
attorney-client privileged and should not, therefore, be disclosed or (iii) the Board of Directors of the Company determines is
reasonably necessary to preserve or protect the exercise of the Board of Directors’ fiduciary duty or to avoid a possible
conflict of interest. GEOF agrees, and any representative of GEOF, including the Observer, will agree, to hold in confidence and
trust and not disclose (other than to GEOF or its affiliates) or use any confidential information provided to or learned by it
in connection with its rights under this letter, provided, that GEOF may give access to such confidential information to its officers,
directors, employees, accountants, counsel and other representatives (collectively, “Representatives”) if each
such Representative is informed of the confidential nature of the information and that the information is subject to a confidentiality
agreement and each such Representative is otherwise under an obligation to keep such confidential information confidential. Each
Observer shall execute a non-disclosure agreement with the Company in form and substance reasonably satisfactory to the Company
prior to commencing his or her role as an Observer. The rights set forth in this Section 6(g) may not be assigned by GEOF without
the prior written consent of the Company.


 




    	-16-



    	 



    

  


7.           OTHER
AGREEMENTS AND COVENANTS


 


(a)      National
Market Listing. Following the Closing, the Company will work with the Purchasers and advisors to qualify for and obtain a full
national market listing of its Common Stock on either the NASDAQ Capital Market or the NYSE MKT. The Company will use commercially
reasonable efforts to qualify and apply for such listing, including effecting a reverse split of its common stock, subject to shareholder
approval, if deemed advisable by a majority of the Board.


 


(b)      Use
of Proceeds. The proceeds from the sale of the Shares and Warrants under this Agreement shall be used for working capital and
general corporate purposes.


 


(c)      Form
D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation
D and, promptly upon request of any Purchaser, to provide a copy thereof. The Company shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers
at each Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide
evidence of such actions promptly upon request of any Purchaser. The Company shall make all filings and reports relating to the
offer and sale of the Securities to the Purchasers required under applicable securities or “Blue Sky” laws of the states
of the United States following each Closing Date.


 


(d)      Reservation
of Shares. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to
issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants, in each case issued as of
the Closing. 


 


(e)      Exchange
Act Filings. Until such time that all of the Securities may be sold without the requirement for the Company to be in compliance
with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, the Company covenants to use commercially
reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the Exchange Act.


 


(f)      Integration.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the
Securities for purposes of the rules and regulations of any trading market such that it would require shareholder approval prior
to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.


 




    	-17-



    	 



    

  


(g)      Expenses.
The Company shall pay the reasonable legal and other fees and expenses of the Purchasers incurred in connection with the transactions
contemplated by this Agreement, up to a maximum of $25,000 in the aggregate, whether or not the Closing occurs. In the event the
Closing occurs, the Company shall pay the reasonable legal fees and expenses of the Purchasers incurred in connection with the
transactions contemplated by this Agreement, up to a maximum of $50,000 in the aggregate. Each party shall otherwise bear all costs
and expenses incurred by such party in connection with the transactions contemplated by this Agreement.


 


(h)      Purchaser/Director
Designee Exchange Act Filings.  Each Purchaser and each Director Designee shall be responsible for the filing (and for all
expenses in connection therewith) of required filings under the Exchange Act and all required amendments thereto relating to ownership
of the Securities and appointment as a member of the Board, including any required Forms 3, 4 and 5 and Schedules 13D or 13G (as
applicable). Each Purchaser and each Director Designee shall use commercially reasonable efforts to file such forms within the
time period allowed for such forms under the rules and regulations promulgated by the SEC.


 


8.           PUBLIC
STATEMENTS


 


The Company shall, by 9:00 a.m. (New York
City time) on the trading day immediately following the date of this Agreement, issue a press release disclosing the material terms
of the transactions contemplated hereby. The Company shall file a Current Report on Form 8-K within the time required by Form 8-K
disclosing the material terms of the transactions contemplated hereby, which Form 8-K shall include this Agreement (including conformed
signature pages thereto), the Registration Rights Agreement (including conformed signature pages thereto) and the form of Warrant
as exhibits thereto. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect
to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise
make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or
without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law.


 


9.           MISCELLANEOUS


 


(a)      Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by the internal laws of the State of Delaware, United States of America, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the
laws of any jurisdictions other than the State of Delaware. If any provision of this Agreement shall be invalid or unenforceable
in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this
Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.


 




    	-18-



    	 



    

  


(b)      Entire
Agreement. This Agreement and the documents referenced herein and therein constitute the entire agreement among the parties
hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings,
other than those set forth or referred to herein and therein. This Agreement and the documents referenced herein and therein supersede
all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof. Without
limiting the foregoing, it is acknowledged and agreed that (i) Section 6 of this Agreement shall supersede and replace Section
6 of the Common Stock Purchase Agreement, dated May 17, 2013, by and among the Company and the purchasers signatory thereto, as
amended on March 31, 2014 and May 30, 2014 (the “2013 Purchase Agreement”) and (ii) the entry into this Agreement
and the consummation of the transactions contemplated hereby are in lieu of any Subsequent Closings (as defined in the 2013 Purchase
Agreement) and Section 2(b) of the 2013 Purchase Agreement shall have no further effect. Notwithstanding the foregoing, the terms
of any confidentiality agreement entered into between the Company and any Purchaser shall remain in full force and effect.


 


(c)      Amendments
and Waivers. Except as otherwise set forth herein, no provision of this Agreement may be waived, modified, supplemented or
amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding at least
a majority in interest of the Shares then outstanding (which amendment shall be binding on all Purchasers) or, in the case of a
waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to
any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of
any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of
any party to exercise any right hereunder in any manner impair the exercise of any such right.


 


(d)      Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); (iii) upon receipt when delivered by email delivery of a “.pdf” format data file or (iv) upon receipt, when
sent via a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same.
The addresses, facsimile numbers and email addresses for such communications shall be:


 


If to the Company:       Interleukin
Genetics, Inc. 


135 Beaver Street

Waltham, MA 02452

Telephone:  (781) 398-0700

Facsimile:    (781) 398-0720

email:            kkornman@ilgenetics.com

Attention:     Kenneth S. Kornman

                       Chief Executive Officer




 




    	-19-



    	 



    

  


with a copy to:           Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 


One Financial Center


Boston, MA 02111


Tel:     (617) 542-6000


Fax:     (617) 542-2241


email:bkeane@mintz.com

Attn: Brian P. Keane, Esq.




 


If to a Purchaser:       To the address
set forth on the signature page to this Agreement.


 


(e)      No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.


 


(f)      Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.


 


(g)      Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.


 


(h)      Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger, consolidation or sale of all or substantially all of the Company’s assets). Except
as specifically set forth herein, any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to
the transferred Securities, by the provisions of this Agreement and the documents referenced herein that apply to the Purchasers.


 


(i)      Survival.
Subject to applicable statute of limitations, the representations and warranties contained herein shall survive the Closing and
the delivery of the Securities hereunder. No investigation by or knowledge of a party or its representatives, before or after the
date of this Agreement, will affect in any manner the representations, warranties, covenants or agreements of another party set
forth in this Agreement (or in any document to be delivered in connection with the consummation of the transactions contemplated
by this Agreement) or the rights to rely thereon, and such representations, warranties, covenants and agreements will survive any
such investigation.


 




    	-20-



    	 



    

  


(j)      No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person or entity.


 


(k)      Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable third-party costs (including customary indemnity or bond) associated with the issuance of such replacement
Securities.


 


(l)      Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under this Agreement are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or
non-performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein or in any other document
referred to herein, and no action taken by any Purchaser pursuant hereof or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are
in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement.
Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising
out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding
for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of this Agreement
and the other documents referred to herein.


 


(m)      Business
Day. “Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday
in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other
governmental action to close. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein or in the Registration Rights Agreement shall not be a Business Day, then such action may be taken or such right
may be exercised on the next succeeding Business Day.


 


(n)      Headings.
The headings of this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.


 


(o)      Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.


 


[Remainder of page intentionally left blank.
Signature pages follow.]


 




    	-21-



    	 



    

  


IN WITNESS WHEREOF, the parties hereto have
caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.


  


	 	COMPANY:
	 	 	 
	 	INTERLEUKIN GENETICS, Inc.
	 	 	 
	 	By:	/s/ Kenneth S. Kornman
	 	 	Name:  Kenneth S. Kornman
	 	 	Title:  Chief Executive Officer


 


[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.


SIGNATURE PAGES FOR PURCHASERS FOLLOW.]


 




    	 



    	 



    

  


[PURCHASER SIGNATURE PAGES TO INTERLEUKIN
GENETICS, INC. 


SECURITIES
PURCHASE AGREEMENT]


 


IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.


 


Name of Purchaser: See Schedule I
hereto.


 


Signature of Authorized Signatory of
Purchaser: __________________________________


 


Name of Authorized Signatory: ____________________________________________________


 


Title of Authorized Signatory: _____________________________________________________


 


Email Address for Notice to Purchaser:
______________________________________________


 


Facsimile Number for Notice to Purchaser: _____________________________________________


 


Address for Notice to Purchaser:


 


Address for Delivery of Securities to Purchaser (if not same
as address for notice):


 


Purchase Price: $_________________


 


Shares of Common Stock: _________________


 


Warrant Shares: __________________


 


EIN Number: __________________


 


[SIGNATURE PAGES CONTINUE]


 




    	 



    	 



    

  


SCHEDULE I


 


The Purchasers


 





	 	 	 	 
	Purchaser	 	Shares	 	 	Warrants	 	 	Purchase Price	 
	Bay City Capital Fund V, L.P. 
	 	 	25,996,552	 	 	 	25,996,552	 	 	$	2,607,454.17	 
	Bay City Capital Fund V Co-Investment Fund, L.P. 
	 	 	495,400	 	 	 	495,400	 	 	$	49,688.62	 
	Growth Equity Opportunities Fund III, LLC 
	 	 	19,868,965	 	 	 	19,868,965	 	 	$	1,992,857.17	 
	Keith C. Stone	 	 	249,252	 	 	 	249,252	 	 	$	24,999.98	 
	Charles D. Bryceland	 	 	1,994,018	 	 	 	1,994,018	 	 	$	200,000.01	 
	Stephen DiPalma	 	 	249,252	 	 	 	249,252	 	 	$	24,999.98	 
	William Alan Jolly	 	 	747,757	 	 	 	747,757	 	 	$	75,000.03	 
	Michael Jeffrey Reid Charles UAD 4/30/09	 	 	249,252	 	 	 	249,252	 	 	$	24,999.98	 
	Daniel Geffken	 	 	249,252	 	 	 	249,252	 	 	$	24,999.98	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total	 	 	50,099,700	 	 	 	50,099,700	 	 	$	5,024,999.92	 











 




    	 



    	 



    

  


EXHIBIT A


 


See Exhibit 4.1 to the Form 8-K filed on December 23, 2014
(File No. 001-32715)


 




    	 



    	 



    

 


EXHIBIT B


 


See Exhibit 10.2 to the Form 8-K filed on
December 23, 2014 (File No. 001-32715)